With the Supreme Court ruling on Obama Care, much of the business world is focused on healthcare. In honor of that attention, we decided to devote several issues this summer…

John Bigelow, Jun 27, 2012 Cases involving pharmaceuticals settlements to patent litigation with so called “reverse payments” or, as the FTC now prefers to call them, “exclusion payments” have been…

Anne Layne-Farrar, Jun 27, 2012 We are drawing close to the thirtieth anniversary of the Drug Price Competition and Patent Term Restoration Act, better known as Hatch-Waxman, enacted in 1984.…

Kyle Musgrove, Richard Ripley, Jun 27, 2012 In April 2012, the Federal Trade Commission (“FTC”) suffered yet another rebuke of what FTC Chair Jon Leibowitz has characterized as “one of…

Kevin Noonan, Jun 27, 2012 The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding generic drugs. This threat is…

Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012 The Eleventh Circuit’s recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the “AndroGel” decision) addresses the latest challenge to reverse-payment settlements. The…

William Michael, Aidan Synnott, Jun 27, 2012 For over a decade, the Federal Trade Commission has sought, with little success, to end “reverse settlement” payments among manufacturers of branded and…